The role of combination strategies in the treatment of FLT3-mutated acute myeloid leukemia

During the latest AML Hub Steering Committee Meeting on August 11, 2026, key opinion leaders met to discuss the role of combination strategies in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML). The meeting opened with a presentation by Gail J. Roboz, followed by a discussion featuring Agnieszka Wierzbowska, Charles Craddock, Jorge Sierra, Lars Bullinger, and Roland Walter. Roboz reviews the rationale for combination strategies in FLT3m AML and discusses updates presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 29 – June 2, 2026, Chicago, US, and the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE. She considers potential future directions for FLT3 inhibitor-based combination strategies, followed by a discussion focused on how best to translate high remission rates into durable disease control and long-term outcomes. The steering committee also explores how treatment strategies may need to be individualized according to patient fitness, molecular profile, treatment response, and access to available therapies. Intended for healthcare professionals. This educational resource is independently supported by Daiichi Sankyo. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.